摘要
目的:检测多种肿瘤/睾丸抗原相关基因在膀胱癌中的表达状况.方法:用逆转录聚合酶链反应(RTPCR)方法对33例膀胱癌患者癌组织和癌旁正常膀胱组织进行MAGEA1,SSX2,NYESO1,MAGEC1,MAGEE1和HAGE的mRNA表达检测.随机抽取每种CTA基因的3例阳性RTPCR扩增产物的目的片段进行DNA序列测定.结果:33例膀胱癌标本中MAGEA1,SSX2,NY-ESO-1,MAGEC1,MAGEE1和HAGE的表达频率分别为21.2%(7/33),39.4%(13/33),69.7%(23/33),42.4%(14/33),36.4%(12/33)和24.2%(8/33).正常膀胱组织中6种CTA基本无表达.肿瘤组织中6种基因至少有1种表达的频率是75.8%(25/33),两种或两种以上同时表达几率是69.7%(23/33).测序结果表明RTPCR产物确为CTA目的基因序列.结论:CTA在膀胱癌主动免疫治疗中是一种合适的、有前景的攻击靶点.同时,多种CTA的联合表达为多效价CTA疫苗在膀胱癌免疫治疗中的应用提供了理论基础.
AIM: To investigate the genes expression of cancer/testis antigens (CTA) in human bladder cancer. METHODS: Reverse-transcription polymerase chain reaction (RT-PCR) was used to investigate the expression of the MAGEA1, SSX2, NY-ESO-1, MAGEC1, MAGEE1 and HAGE genes in 33 bladder cancer samples and corresponding non-tumorous bladder tissues. Three samples randomly selected from each CTA PCR product were sequenced. RESULTS: In the 33 tumor samples, the MAGEA1, SSX2, NY-ESO-1, MAGEC1, MAGEE1 and HAGE mRNA expression rates were respectively 21.2% (7/33), 39.4% (13/33), 69.7% (23/33), 42.4% (14/33), 36.4% (12/33) and 24.2% (8/33). In tumor tissues, the positivity rate was found to be 75.8% (25/33) for at least one of these genes expression, and 69.7% (23/33) for two and more than two. Almost none of the non-tumorous bladder tissues were positive for these genes. The DNA sequence confirmed that the RT-PCR products were CTA cDNA. CONCLUSION: The cancer/testis antigens are potential targets for antigen-specific immunotherapy of bladder cancer. The coexpression pattern of these antigens provides a theoretic foundation for the development of a polyvalent bladder cancer vaccine.
出处
《第四军医大学学报》
北大核心
2005年第11期1026-1028,共3页
Journal of the Fourth Military Medical University
基金
陕西省科技攻关计划项目(200210G4)
